Mostrar el registro sencillo del ítem

dc.contributor.author
Marcora, Maria Silvina  
dc.contributor.author
Fernandez Gamba, Agata Claudia  
dc.contributor.author
Avendaño, Luz A  
dc.contributor.author
Rotondaro, Cecilia  
dc.contributor.author
Podhajcer, Osvaldo Luis  
dc.contributor.author
Vidal, Rubén  
dc.contributor.author
Morelli, Laura  
dc.contributor.author
Ceriani, Maria Fernanda  
dc.contributor.author
Castaño, Eduardo Miguel  
dc.date.available
2016-11-29T21:14:22Z  
dc.date.issued
2014-01  
dc.identifier.citation
Marcora, Maria Silvina; Fernandez Gamba, Agata Claudia; Avendaño, Luz A; Rotondaro, Cecilia; Podhajcer, Osvaldo Luis; et al.; Amyloid peptides ABri and ADan show differential neurotoxicity in transgenic Drosophila models of familial British and Danish dementia; Biomed Central; Molecular Neurodegeneration; 9; 5; 1-2014; 1-14  
dc.identifier.issn
1750-1326  
dc.identifier.uri
http://hdl.handle.net/11336/8479  
dc.description.abstract
BACKGROUND: Familial British and Familial Danish dementias (FBD and FDD, respectively) are associated with mutations in the BRI2 gene. Processing of the mutated BRI2 protein leads to the accumulation in the brain of the 34-mer amyloid Bri (ABri) and amyloid Dan (ADan) peptides, accompanied by neurofibrillary tangles. Recently, transgenic mice successfully reproduced different aspects of FDD, while modeling of FBD in vivo has been more difficult. In this work we have modeled FBD and FDD in Drosophila and tested the hypothesis that ABri and ADan are differentially neurotoxic. RESULTS: By using site-directed insertion, we generated transgenic lines carrying ABri, ADan, Bri2-23 (the normal product of wild-type BRI2 processing) and amyloid-β (Aβ) 1-42 as a well-characterized neurotoxic peptide, alone or with a His-tag. Therefore, we avoided random insertion effects and were able to compare levels of accumulation accurately. Peptides were expressed with the GAL4-Upstream Activating Sequence (UAS) system using specific drivers. Despite low levels of expression, toxicity in the eye was characterized by mild disorganization of ommatidia and amyloid peptides accumulation. The highest toxicity was seen for ADan, followed by Aβ42 and ABri. Pan-neuronal expression in the CNS revealed an age-dependent toxicity of amyloid peptides as determined by the ability of flies to climb in a geotaxis paradigm when compared to Bri2-23. This effect was stronger for ADan, detected at 7 days post-eclosion, and followed by ABri and Aβ42, whose toxicity became evident after 15 and 21 days, respectively. Histological analysis showed mild vacuolization and thioflavine-S-negative deposits of amyloid peptides. In contrast, the over-expression of amyloid peptides in the specific subset of lateral neurons that control circadian locomotor activity showed no toxicity. CONCLUSIONS: Our results support the differential neurotoxicity of ADan and ABri in the Drosophila eye and CNS at low expression levels. Such differences may be partially attributed to rates of aggregation and accumulation. In the CNS, both peptides appear to be more neurotoxic than wild-type Aβ42. These Drosophila models will allow a systematic and unambiguous comparison of differences and similarities in the mechanisms of toxicity of diverse amyloid peptides associated with dementia.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Biomed Central  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Alzheimers Disease  
dc.subject
Familial British Dementia  
dc.subject
Familial Danish Dementia  
dc.subject
Abri  
dc.subject
Adan  
dc.subject
Neurotoxicity  
dc.subject
Drosophila  
dc.subject.classification
Neurociencias  
dc.subject.classification
Medicina Básica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Amyloid peptides ABri and ADan show differential neurotoxicity in transgenic Drosophila models of familial British and Danish dementia  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2016-11-25T16:34:38Z  
dc.journal.volume
9  
dc.journal.number
5  
dc.journal.pagination
1-14  
dc.journal.pais
Reino Unido  
dc.journal.ciudad
Londres  
dc.description.fil
Fil: Marcora, Maria Silvina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquimicas de Buenos Aires; Argentina. Fundación Instituto Leloir; Argentina  
dc.description.fil
Fil: Fernandez Gamba, Agata Claudia. Fundación Instituto Leloir; Argentina  
dc.description.fil
Fil: Avendaño, Luz A. Fundación Instituto Leloir; Argentina  
dc.description.fil
Fil: Rotondaro, Cecilia. Fundación Instituto Leloir; Argentina  
dc.description.fil
Fil: Podhajcer, Osvaldo Luis. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquimicas de Buenos Aires; Argentina. Fundación Instituto Leloir; Argentina  
dc.description.fil
Fil: Vidal, Rubén. Indiana University School of Medicine. Indiana Alzheimer Disease Center. Department of Pathology and Laboratory Medicine; Estados Unidos  
dc.description.fil
Fil: Morelli, Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquimicas de Buenos Aires; Argentina. Fundación Instituto Leloir; Argentina  
dc.description.fil
Fil: Ceriani, Maria Fernanda. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquimicas de Buenos Aires; Argentina. Fundación Instituto Leloir; Argentina  
dc.description.fil
Fil: Castaño, Eduardo Miguel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquimicas de Buenos Aires; Argentina. Fundación Instituto Leloir; Argentina  
dc.journal.title
Molecular Neurodegeneration  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-9-5  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1186/1750-1326-9-5  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898387/